Abiomed-backed Shockwave Medical has raised approximately $97m in an oversubscribed initial public offering, before its shares climbed more than 85% by the end of Friday.
Shockwave Medical, a US-based calcification treatment system developer backed by medical implant manufacturer Abiomed, has secured $97m in an initial public offering on the Nasdaq Global Select Market.
The company sold 5.7 million shares priced at $17 each, approximately 700,000 more than it had originally planned and above its target range of $14 to $16. It floated on Thursday and its shares closed at $31.61 on Friday, an increase of more than 85% on the IPO price, giving Shockwave…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
